Amylyx Pharmaceuticals Receives Notification of PDUFA Date Extension for AMX0035 for the Treatment of ALS
New PDUFA goal date scheduled for September 29, 2022 to allow time to review additional data
CAMBRIDGE, Mass.--(BUSINESS WIRE) June 3, 2022 -- Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the“Company”)...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news
More News: Drugs & Pharmacology | New Drug Applications